Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
12:09pm, Monday, 17'th Nov 2025
Zymeworks Inc. (NASDAQ: ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.
Why Jazz (JAZZ) International Revenue Trends Deserve Your Attention
10:16am, Monday, 17'th Nov 2025
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.
08:10am, Monday, 17'th Nov 2025
The companies' drug Ziihera shows clinically meaningful benefits for patients with gastroesophageal adenocarcinoma.
Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend t
Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend t
Data highlight continued progress in Jazz's brain tumor research and demonstrate the company's commitment to advancing treatment options for patients with rare and aggressive brain tumors For U.S. med
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
11:51am, Thursday, 06'th Nov 2025
Jazz Pharmaceuticals posts strong Q3 results with higher EPS and sales, aided by a tax benefit and robust neuroscience growth.
Jazz Pharmaceuticals plc (JAZZ) Q3 2025 Earnings Call Transcript
08:41pm, Wednesday, 05'th Nov 2025
Jazz Pharmaceuticals plc ( JAZZ ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jack Spinks - Executive Director of Investor Relations Renée Galá - President, CEO & Directo
Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
08:00pm, Wednesday, 05'th Nov 2025
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates
06:36pm, Wednesday, 05'th Nov 2025
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $8.13 per share, beating the Zacks Consensus Estimate of $5.74 per share. This compares to earnings of $6.61 per share a year ago.
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
04:05pm, Wednesday, 05'th Nov 2025
– Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG – – Zepzelca ® and atezolizumab (Tecentriq ® ) combination approved as maintenance therapy in 1L ES-SCLC
Aristotle Global Equity Advisory Q3 2025 Contributors And Detractors
02:24pm, Sunday, 02'nd Nov 2025
MonotaRO, the Japanese business-to-business (B2B) e-commerce platform, was the largest detractor during the quarter. Pawn shop operator FirstCash was the top contributor during the quarter. Aggregates
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline
11:08am, Wednesday, 29'th Oct 2025
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals Appoints Ted W. Love, M.D.
04:05pm, Tuesday, 28'th Oct 2025
Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value DUBLIN , Oct. 28, 2025 /PRNewswire/ -- Jazz
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
04:15pm, Wednesday, 22'nd Oct 2025
DUBLIN , Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5, 2025, after the c
